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Late effects in the Lung
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Radiation-induced pneumonitis and fibrosis are dose-limiting side effects of thoracic 
irradiation. Thoracic irradiation triggers acute and chronic environmental lung changes 
that are shaped by the damage response of resident cells, by the resulting reaction of 
the immune system, and by repair processes. Although considerable progress has been 
made during the last decade in defining involved effector cells and soluble mediators, 
the network of pathophysiological events and the cellular cross talk linking acute tissue 
damage to chronic inflammation and fibrosis still require further definition. Infiltration of 
cells from the innate and adaptive immune systems is a common response of normal 
tissues to ionizing radiation. Herein, lymphocytes represent a versatile and wide-ranged 
group of cells of the immune system that can react under specific conditions in various 
ways and participate in modulating the lung environment by adopting pro-inflammatory, 
anti-inflammatory, or even pro- or anti-fibrotic phenotypes. The present review provides 
an overview on published data about the role of lymphocytes in radiation-induced 
lung disease and related damage-associated pulmonary diseases with a focus on T 
lymphocytes and B lymphocytes. We also discuss the suspected dual role of specific 
lymphocyte subsets during the pneumonitic phase and fibrotic phase that is shaped by 
the environmental conditions as well as the interaction and the intercellular cross talk 
between cells from the innate and adaptive immune systems and (damaged) resident 
epithelial cells and stromal cells (e.g., endothelial cells, mesenchymal stem cells, and 
fibroblasts). Finally, we highlight potential therapeutic targets suited to counteract 
pathological lymphocyte responses to prevent or treat radiation-induced lung disease.
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iNTRODUCTiON
About 60% of all cancer patients receive radiotherapy (RT) at some point during the course of 
their disease, and good results in terms of long-term survival and tumor cure are achieved in 
a variety of tumors by multimodal combinations of surgery, RT, and chemotherapy. Concurrent 
radiochemotherapy could improve the prognosis of glioma, lung, head and neck, esophageal, 
cervical, anal, and rectal cancer (1–8) and is part of standard therapy for locally advanced tumors 
of these entities. Yet, treatment outcome is still unsatisfactory for common forms of cancer with 
high loco-regional failure rates or frequent development of metastases. Although patient-specific 
clinical factors may explain some of these failures, it is commonly assumed that biological factors 
adversely affecting the response of tumor cells to treatment, such as intrinsic radioresistance, tumor 
FiGURe 1 | Schematic representation showing the phases of radiation-induced lung injury over time with a view on the dual role of lymphocytes 
during radiation-induced pneumopathy. Damage to the lung results in an initial response (acute radiation response) due to DNA damage, ROS induction, and 
apoptosis. Release of damage-associated molecular patterns (DAMPs) and secretion of cytokines and chemokines activate the immune system. This phase 
passes over into an acute inflammatory phase (pneumonitis) that is characterized by an enhanced pro-inflammatory response and vascular leakage. In this phase, 
diverse lymphocyte subpopulations like TH1, TH17, and potentially innate lymphoid cells (ILC) can contribute to inflammation, whereas it is believed that the 
lymphocyte subpopulations Treg are needed to control harmful, excessive pro-inflammatory responses. Resolution of inflammation and repair induction is paralleled 
by late mitotic cell death subsequent, hypoxia, release of DAMP, cytokines, and growth factors. These alterations in the lung micromilieu are described for the 
chronic phase of radiation-induced pneumopathy. These environmental changes can contribute to immunomodulation; here, it is believed that lymphocytes (TH2, 
TH9, Treg, and potentially ILC) show an anti-inflammatory or even pro-fibrotic phenotype, thereby having the potential to further alter the environment in the lung 
toward the induction of disease-promoting myofibroblasts and fibrosis development.
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promoting mutations, unfavorable gene expression profiles, 
heterogeneity in radiation responses, or a resistance-promoting 
microenvironment, significantly contribute to treatment failures 
(9–14). Acute and late toxicity to normal tissues also limits the 
radiation dose that can be applied to the tumor, and tolerable 
doses are often linked to suboptimal tumor control—even 
accepting side effects that lead to decreased quality of life (15). 
Normal tissue toxicity also precludes therapy intensification 
efforts for many locally advanced tumors by the combination 
with cytotoxic chemotherapy (16–18). As a consequence, there 
is high interest in improving the therapeutic ratio either by 
technical and physical innovations in treatment delivery, e.g., 
intensity-modulated radiation therapy or particle therapy, or by 
developing effective strategies to prevent or treat the toxic effects 
of ionizing radiation (IR) in normal tissues without protect-
ing the tumor cells, or to increase intrinsic radiosensitivity of 
cancer cells without increasing sensitivity of normal tissue cells, 
respectively.
Dose-limiting side effects in the lung tissue after RT of the tho-
racic region or total body irradiation in conditioning regimens 
for hematopoietic stem cell transplantation include inflamma-
tory (pneumonitis) and fibrotic changes (pulmonary fibrosis) 
(19–21). Radiation-induced damage to the lung tissue leads, 
like infectious, thermal, or physical damage, to the activation 
of the immune system. This inflammatory response is needed 
to orchestrate tissue repair and regeneration in order to restore 
tissue homeostasis. Depending on the degree of the resulting 
aseptic inflammation, patients can present with pneumonitis. 
Radiation-induced pneumonitis can develop at 4–12 weeks after 
RT with symptoms like fever, chest pain, dry cough, and dyspnea 
or even respiratory failure in severe cases and occurs in 5–20% 
of patients with lung or breast cancer (22–24). The pneumonitic 
phase is characterized by the recruitment of diverse immune 
cells of myeloid and lymphoid origin and a perpetual cascade 
of cytokines/chemokines resulting in various degrees of lung 
inflammation and the described symptoms (Figure 1).
FiGURe 2 | How the microenvironment shapes the immune response and vice versa. We hypothesize that radiation induces damage to tissue resident cells, 
e.g., endothelial and epithelial lung cells, mesenchymal stem cells (MSC) as well as in resident immune cells. The resulting tissue damage can initiate stress 
responses or cell death with subsequent release of cytokines/chemokines and damage-associated molecular patterns (DAMPs). This initial damage response leads 
to the recruitment and activation of diverse immune cells to the lung, among them lymphocytes. Further activation, proliferation of these cells, and secretion of 
cytokines shape the pulmonary micromilieu toward inflammation and—if this response is too excessive—to the development of severe pneumonitis. Late chronic 
mitotic cell death and subsequent tissue hypoxia lead to the release of DAMPs and cytokines/chemokines from resident cells thereby altering the micromilieu in the 
lung. These environmental changes impact on the immune cells present in the lung tissue and promote an altered cytokine release of immune cells. Finally, epithelial-
mesenchymal-transition, endothelial-mesenchymal-transition, mesenchymal stem cell differentiation, and the altered environment contribute to the induction of 
activated myofibroblasts, collagen deposition, and fibrosis.
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Development of radiation-induced lung fibrosis is mostly 
observed 6–24  months after RT and may become chronic in 
patients with a large irradiated lung volume (24). Major symp-
toms of lung fibrosis are breathing difficulties and subsequent 
volume loss of the lung (25). Studies from various groups using 
rodent models and patient samples helped to reveal a complex 
response of the lung tissue toward irradiation with multiple 
interactions between resident lung cells including lung-resident 
mesenchymal stem cells (MSC), locally generated or recruited 
fibroblasts, and infiltrating immune cells, respectively (26–37). 
We speculate that a sophisticated network between damaged 
resident cells (epithelial cells, endothelial cells, and lung-
resident MSC), recruited immune cells, and soluble mediators 
(cytokines, chemokines, growth factors, and proteases) and 
the resulting environmental changes participate in shaping the 
observed inflammatory and fibrotic alterations of the lung tissue 
(Figures 1 and 2).
Among other molecular markers there is evidence from 
preclinical and clinical studies that T lymphocytes infiltrate the 
lung to a considerable extent, particularly during the pneumo-
nitic phase at 3–12 weeks post-irradiation, although lymphocyte 
infiltration was also observed at later time points during the 
chronic inflammatory/fibrotic phase at 16–30 weeks post-irra-
diation (30, 35, 38–40). Interestingly, earlier studies described 
a correlation between the presence of CD4+ T cells in the bron-
choalveolar lavage of irradiated breast or lung cancer patients 
and the development of pneumonitis (39, 41, 42). Furthermore, 
depletion of CD4+ T cells during the pneumonitic phase attenu-
ated the development of lung fibrosis upon thoracic irradiation 
in a murine model (43). These findings suggest a complex role 
of CD4+ T cells in the pathogenesis of radiation-induced lung 
disease. Antibody-mediated inhibition of the accumulation of 
CD3+ lymphocytes or depletion of CD4 and CD8 T lymphocytes 
also reduced fibrosis levels in the murine model of pulmonary 
fibrosis induced by the radiomimetic and DNA-damaging drug 
bleomycin (BLM) (44, 45). In contrast, the lack of mature T 
and B lymphocytes in recombination-activating gene 2 (RAG2)-
deficient mice exacerbated radiation-induced fibrosis (46). 
Altogether, these findings highlight that lymphocytes play a 
complex role in DNA damage-induced lung disease and sug-
gest that depending on the disease stage and the environmental 
conditions, shaped by the tissue response to the damage, specific 
lymphocyte subpopulations exert either beneficial or adverse 
effects (Figure 1). We propose that a disturbed balance between 
tissue inflammation and repair processes participates in the 
development of radiation-induced pulmonary fibrosis as it has 
been described for other fibrotic diseases and that lymphocytes 
are involved in these processes (47). Nevertheless, it remains 
to be demonstrated whether lymphocytes directly contribute 
to radiation-induced lung disease or only modulate disease 
progression. Furthermore, it remains to be explored whether, 
besides the myeloid compartment, innate lymphoid cells (ILC) 
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might contribute to radiation-induced fibrosis. Finally, the 
mechanisms driving radiation-induced lymphocyte deviation 
remain to be defined.
LYMPHOCYTeS: eFFeCTOR CeLLS 
OF THe iMMUNe SYSTeM
Lymphocytes are characterized as white blood cells that are 
homogeneous in appearance but that have various functions. 
They include T cells, B cells, and ILC among them conventional 
natural killer (NK) cells. T cells, ILC, and B cells are responsible 
for the production of cytokines and antibodies (B cells), whereas 
NK cells can induce direct cell-mediated killing of virus-infected 
cells and tumor cells. Here, we will focus on a potential role of B 
and T lymphocytes as well as ILC.
The different major subpopulations of T lymphocytes include 
CD8+, CD4+ T cells, NK T cells, and γδT cells. CD8+ T cells 
comprise cytotoxic T cells or cytolytic T cells. They control and 
eliminate intracellular pathogens and tumor cells and can further 
differentiate into CD8+ memory cells (48). γδT cells express a T cell 
receptor differing from the conventional αβT cells. The function 
of γδT cells is poorly understood, but current knowledge implies 
a role in immunoregulation in pathogen and allergen responses 
(49). NK T cells are a unique subpopulation of lymphocytes that 
are mainly involved in innate immunity and will not be further 
discussed in the present review.
CD4+ T cells comprise TH1 and TH2 subpopulations. Further-
more, advances in immunology have led to the characterization 
of newly appreciated CD4+ T cell effector populations that regu-
late the immune response such as interleukin (IL)-17-producing 
T cells (TH17 cells), T cells with regulatory function [regulatory 
T  cells (Treg)], IL-9-secreting TH9 cells, IL-22-dominant TH22 
cells, and B cell-interacting follicular helper T cells (TFH), thus 
revising established paradigms (50–58).
The secretion of interferon (IFN)-γ and the directed elimina-
tion of intracellular pathogens characterize a TH1 response. In 
contrast, TH2 responses are shaped by the cytokines IL-4 and 
IL-13, supporting the defense against parasites, and moreover 
contribute to the generation of antibodies (59).
TH17 cells preferentially produce IL-17A-F and play a role in 
inflammatory processes such as autoimmune diseases and the 
defense against extracellular pathogens. TH17 cells further pro-
duce the cytokines IL-21, IL-22, and IL-23, which exert strong 
pro-inflammatory effects (60). TH17 cells are induced by IL-6, 
IL-21, and transforming growth factor beta (TGF-β), a potent 
regulator of lung homeostasis as well as in  pathologies (61, 62).
Another important subpopulation of T cells are Treg. Treg show 
a suppressive capacity, control immune reactions, and inhibit 
exaggerated inflammation (60, 63). Treg exist as natural occurring 
Treg (nTreg) and induced Treg (iTreg). Murine thymus-derived nTreg 
are CD4+/CD25+ and express the transcription factor FoxP3 
(murine cell marker), whereas in humans not all Treg express 
FoxP3. Therefore, Treg in humans are mainly characterized via the 
marker profile CD4+/CD25hi/CD127low (64). Treg show their sup-
pressive capacity by secreting anti-inflammatory cytokines like 
IL-10 and TGF-β, which can induce cell cycle arrest or apoptosis 
in T effector cells.
Recent studies also revealed a small population of CD8+ 
Treg at steady state; these CD8+ Treg are present in the human 
and the murine system, and they express the marker CD25 as 
well as FoxP3. Churlaud et al. showed that CD8+ Treg are highly 
suppressive and responsive to IL-2 (65), but further studies are 
needed to uncover the origin and the role of CD8+ Treg in health 
and pathologies.
B lymphocytes represent the second heterogeneous group of 
lymphocytic cells. B cells originate from the bone marrow, mature 
in the spleen, and differentiate in the lymph nodes into germinal 
center cells after contact with antigens and T cells (66, 67). Besides 
their capacity for antibody secretion, they have functions in 
antigen presentation and secretion of diverse cytokines (68, 69).
The newly identified group of the lymphoid cells, namely 
ILC, plays an important junction between innate and adaptive 
immunity. Like other lymphoid cells, they originate from a com-
mon lymphoid progenitor in the bone marrow. But in contrast 
to their relatives, they lack (RAG)-dependent rearrangement of 
antigen receptors as well as phenotypical markers of myeloid 
and dendritic cells (70, 71). ILC have been characterized by 
their expression pattern of the master transcription factors 
(T-bet, GATA3, and RORγt) and specific cytokines that usually 
define T cell subpopulations. Based on this categorization, three 
different subpopulations (ILC1, ILC2, and ILC3) have been 
defined as follows: (i) ILC1 cells include conventional NK cells 
and T-bet+/IFN-γ-producing cells; (ii) ILC2 cells show GATA3 
expression, and they secrete TH2 cytokines, IL-4, IL-5, IL-9, and 
IL-13 in response to IL-25 and IL-33; and (iii) ILC3 cells express 
the transcription factor RORγt, and they release the cytokines 
IL-17, IL-22, granulocyte–macrophage colony-stimulating factor 
(GM-CSF) as well as lymphotoxins. ILC act on tissue homeostasis 
and tissue remodeling; moreover, they participate in regulating 
immune responses to inflammation and infection in tissues like 
liver, lymph nodes, and mucosal barriers like gut and lung (72, 
73). These characteristics make it highly likely that ILC also 
modulate the progression of radiation-induced lung inflamma-
tion and fibrosis (see Role of Lymphocytes in the Defense of the 
Lung Tissue).
ROLe OF LYMPHOCYTeS iN THe 
DeFeNSe OF THe LUNG TiSSUe
In the lung, T cells are found in relatively high numbers in the 
mucosa, in the intraepithelial part, in the underlying lamina 
propria, and also in the lung parenchyma. T cells of the intraepi-
thelial region express CD8, while CD4 is the dominant surface 
marker of T cells in the lamina propria. Furthermore, it has been 
described that CD45RO is expressed on both, CD4 and CD8 
T cell subsets, indicating their role as effector and/or memory 
cells (74). For CD8+ T cells it is known that they protect the lung 
against influenza infection. Nevertheless, there it is believed that 
CD8+ T cells also contribute to lung injury, e.g., during influenza 
infection due to their cytotoxic effects and the massive produc-
tion of the pro-inflammatory cytokines IFN-γ and tumor necrose 
factor (TNF)-α (75), respectively.
Among the CD4+ T cells, lung TH17 cells may not only play a 
role in neutrophil recruitment and pathogen clearance but also 
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be highly relevant in respiratory inflammatory diseases (76). 
Moreover, a recent study demonstrated that TH17 cells also play a 
role in lung cancer progression: here, the authors analyzed blood 
samples from patients and described that TH17 as well as Treg sub-
sets are involved in the immunopathology of NSCLC (77). In other 
studies, Treg were found to counteract the inflammation-induced 
injury to the airways associated with lung infections as well as the 
development of atopic diseases. Treg also play a role in mediating 
inhalation tolerance and in controlling allergen-specific T cells 
from activation (74, 78). Interestingly, there is evidence from 
some studies that Treg contribute to fibrotic diseases in the lung 
by promoting a pro-fibrotic microenvironment (79–81).
Also, γδ T cells show functions in the airways. For the lungs it 
is described that γδ T cells reside in the subepithelium of alveolar 
and non-alveolar regions (82). Here, they modulate immune 
responses against allergens and pathogens (49, 83). A study from 
Simonian et  al. also revealed a role in inflammation (hyper-
sensitivity pneumonitis)-induced lung fibrosis. Here, γδ T cells 
diminished CD4+ cell recruitment by the secretion of regulatory 
IL-22 thereby protecting the lung from fibrosis (84).
However, the role of TH9, TH22, and TFH cells in lung patholo-
gies is still underexplored. So far, current studies hint to a role for 
TH22 and TFH cells in host defense against viruses and bacteria 
in the lung, whereas TH9 cells seem to play an important role in 
asthma (85–87).
Similar to T cell populations, B cells are also present in the 
parenchymal lung as well as in the conducting airways. In the 
lamina propria, they act as antibody-secreting plasma cells 
producing immunoglobulin (Ig)A but may also contribute to 
local antigen presentation (74, 88). In the lung, B cells can act, for 
example, as memory B cells producing IgA and IgG neutralizing 
antibodies that have the ability to protect against pulmonary viral 
reinfections (89).
The group of ILC is in the focus of current research. ILC have 
been implicated in immunity of the mucosal barrier in the lung, 
e.g., in allergic asthma, hyper responsiveness, and viral infection 
(90–93). The present knowledge on ILC has nicely been sum-
marized in two recent reviews with a focus on their roles in the 
lung tissue (94, 95). Though these reviews emphasize that the role 
of ILC in the lung is still poorly characterized, we will highlight 
some important observations at this point. Among the three ILC 
subsets defined so far, ILC2 present the main ILC in the murine 
lung, but with 2–3 × 104 cells per lung and thus 0.4–1% of total 
lung cells, these ILC seem to be a relatively rare population, at least 
under physiological conditions (91). But, pathological conditions 
in the lung are associated with changes in the ILC population 
(96). In this context, ILC2 and ILC3 seem to play more imported 
roles than ILC1 during chronic lung disease in both, mice and 
men (94, 97, 98). For example, in patients with chronic obstruc-
tive pulmonary disease (COPD) ILC3 constitute the major 
population with 60% of all ILC, whereas ILC2 amount to 30% and 
ILC1 to 10% of the ILC (98). Of note, depletion of ILC2 reduced 
epithelial integrity, induced epithelial degeneration, and impaired 
lung functions during influenza virus infection highlighting a 
protective role of ILC2 for these processes (91).
First reports suggest that ILC may also play an important role 
during acute pulmonary inflammation. In this context, ILC3 
have recently been identified as a major source of IL-17A thereby 
inducing neutrophil recruitment in a murine model of LPS-
induced acute respiratory distress syndrome (99). Furthermore, 
in eosinophilic crystalline pneumonia, a murine idiopathic type 
2 lung inflammation, IL-2 was shown to function as an impor-
tant activator of ILC2 functions; the authors further highlight 
a potential cross talk between ILC2 and ILC3 as well as T cells 
and Treg during disease pathogenesis (100). Even more important, 
in a murine model for allergic asthma, pulmonary epithelial 
cell-derived TGF-β1 and IL-33 contributed to ILC2-mediated 
responses (101).
Besides their effects on acute pulmonary responses, ILC also 
impact the development of pulmonary fibrosis [for a recent 
review, refer to Ref. (102)]. In this context, an interplay between 
ILC, macrophages, and cells of the adaptive immune system was 
shown to participate—together with IL-13, IL-25, and IL-33—in 
the pathogenesis of BLM-induced pulmonary fibrosis in mice 
(103–105). Moreover, Hams et  al. also found elevated levels of 
IL-25 and ILC2 in the lungs of patients with idiopathic pulmo-
nary fibrosis (IPF) (105, 106), whereas others described a role for 
ILC2 and ILC3 in fibroblast activation providing a mechanistic 
link between ILC and fibrotic diseases (102).
Since work from our own laboratory and others implicate 
TH17 cells and Treg in the pathogenesis of radiation-induced lung 
disease, these observations strongly suggest that ILC, particularly 
ILC2 and ILC3, might also participate in the cross talk between 
damaged resident cells, recruited immune cells, and activated 
fibroblasts and thus modulate the extent of lung inflammation 
and progression of radiation-induced fibrosis. But, an involve-
ment of ILC in radiation-induced pneumopathy remains to be 
demonstrated, and potential beneficial or disease-promoting 
effects during the different disease stages (inflammation, fibrosis) 
have to be explored.
iMPACT OF iONiZiNG RADiATiON 
ON LYMPHOCYTeS
Radiation therapy is an essential and common approach in cancer 
treatment. So far, the use of IR in cancer treatment is based on its 
high potential to induce tumor cell death and to abrogate survival 
of clonogenic tumor cells. The toxic effects of IR result from the 
deposition of energy from IR in tumor and normal tissue cells 
including immune cells. Energy deposition results in damage to 
cellular macromolecules, particularly cellular DNA, e.g., by direct 
breakage of chemical bonds within the DNA as well as by the 
generation of free radicals (107, 108). Among the diverse damag-
ing effects of IR, the induction of DNA double strand breaks is 
considered as the most toxic lesion in cells.
The hematopoietic compartment is particularly sensitive to 
IR, for example, blood sample analysis revealed the rapid devel-
opment of a hematopoietic syndrome in patients exposed to a 
total body irradiation of 1–2 Gray (Gy), which was characterized 
by a decline of the hematopoietic compartment (109). Similar to 
other hematopoietic cells, lymphocytes are particularly sensitive 
to radiation-induced cell death. Nevertheless, the various lym-
phocyte subtypes differ in their radiosensitivity: up to now it has 
been demonstrated that B cells, naive T cells, and NK cells are 
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highly radiosensitive, whereas T memory cells, NK T cells, and 
Treg cells are more resistant to the toxic effects of IR (110–114). 
Moreover, a study from 1995 revealed a higher radiosensitivity of 
IL-4-producing TH2 cells compared to TH1 cells (115). Based on 
their high radiosensitivity and easy accessibility, blood lympho-
cytes are frequently used in biodosimetry (116–119).
Further direct effects described in irradiated lymphocytes 
concentrate on the transcriptional response of these cells to IR, 
e.g., by gene expression profiling. These studies revealed that a 
majority of the strongly activated genes are p53 targets, like DNA 
damage-binding protein 2, the BCL-2-associated gene BAX, 
and tumor necrosis factor receptor superfamily, member 10b 
(TNFRSF10B) that are involved in DNA repair and apoptosis 
regulation (120–122).
However, in addition to these direct or “targeted” effects of IR 
on lymphocytes such as the induction of cellular stress responses 
and cell death in lymphocytes within the radiation field, lympho-
cytes can also mount an indirect response to radiation-induced 
tissue damage. In this context, “danger signals” released from 
damaged or dying cells in irradiated tissues result in lymphocyte 
activation, infiltration into the damaged tissue, and the release of 
inflammatory mediators (Figure 2).
Of note, high-dose irradiation also efficiently triggers direct 
tumor cell death and augments innate immune responses and 
tumor-specific immunity thereby enhancing the local and distant 
antitumor effects of RT. This was nicely summarized by one of 
the pioneers in the filed of radioimmunotherpy, Silvia Formenti 
(123). Accordingly, high numbers of tumor-infiltrating cytotoxic 
lymphocytes may predict the response of certain tumors to treat-
ments involving RT (105, 124). This is a hot topic in the field 
of radiation biology and oncology highlighted in other reviews; 
here, we will concentrate on the contribution of radiation-induced 
modulation of the lymphocyte compartment to the adverse late 
effects of IR in the lung.
ROLe OF LYMPHOCYTeS iN THe 
iRRADiATeD LUNG
As nicely highlighted in a recent review on the general effects of 
IR on T lymphocytes and normal tissue responses, our under-
standing of the interaction between lymphocytes and radiation-
induced tissue damage is still rudimentary (125). Because of the 
complexity of the involved cellular systems and soluble factors, 
investigations about the mechanisms underlying radiation-
induced adverse late effects, for example, in the lung can only be 
performed in patients as well as animal models in vivo, particu-
larly rodent models.
importance of the experimental Model
Experimental models that use a single high-dose whole thorax 
or hemithorax irradiation of fibrosis-sensitive mice (C57BL/6) 
mimic human disease with respect to the time course and 
major symptoms of the disease (pneumonitis, fibrosis) and are 
therefore frequently used to study the underlying mechanisms, 
to define disease biomarkers and novel therapeutic targets, 
and to explore potential toxic effects of new combination 
strategies using IR in combination with molecularly targeted 
drugs (26, 126–130).
In this context, it is important to consider that mice with 
different backgrounds differ in their sensitivity to acute and 
chronic responses (pneumonitis, fibrosis), and these differences 
seem to be associated with differences in immune response in 
fibrosis-sensitive (C57BL/6, C57BL/6J) and fibrosis-resistant 
mice (e.g., BALB/c, C3Hf, and A/J) (131–133). In support of this 
assumption, a comparison of the transcriptome of lung tissue of 
fibrosis-prone C57BL/6J or fibrosis-resistant C3Hf/KAM mice 
upon BLM treatment revealed that the differences between the 
mouse strains included genes important for apoptosis, oxidative 
stress, and immune regulation (134).
On the other hand, due to the long latency of radiation-
induced adverse side effects, researchers frequently use local 
or systemic administration of the DNA-damaging drug BLM 
as a radiomimetic drug that rapidly provokes a pronounced 
lung fibrosis in rodent models (135). However, work from our 
own group and from others suggests that the impact of the 
immune system on disease outcome may play different roles 
in the BLM and RT model, particularly when the acute model 
of intratracheal application of BLM is used (35, 136, 137). 
Since the C57BL/6 model is suited for the analysis of both, 
pneumonitis and fibrosis, we focus particularly on this model 
in the subsequent paragraphs. But, we are aware of the fact that 
future studies are needed in a more clinically relevant setting 
with fractionated irradiation.
Investigations in rodent models using experimental whole 
thorax or hemithorax irradiation are still underrepresented. 
Thus, preclinical studies about the contribution of RT-induced 
immunomodulation in normal tissues to radiation-induced lung 
disease are rare particularly with respect to lymphocyte responses. 
We therefore included data about lymphocytes responses 
from studies in other models of chronic respiratory disease or 
pulmonary fibrosis, where appropriate. We are aware that the 
described models are different with respect to the initial injury, 
the time course, and some of the involved mediators. However, 
from an immunological point of view, the different models of 
(chronic) inflammation/fibrosis share a sterile inflammation/
repair/remodeling response to an initial damage/trauma and will 
therefore help to understand lymphocyte responses in the lung in 
response to radiation-induced tissue damage.
early effects of Thoracic irradiation on 
Lymphocytes in the Lung
Early immune suppression with subsequent lymphocyte infiltra-
tion are common responses of irradiated tissues during the acute 
and chronic phase after irradiation, including the lung tissue (40, 
42, 138, 139). Preclinical studies in mice corroborated the infiltra-
tion and reconstitution of lymphocytes observed in patients (for 
more details, see Table  1). For example, Paun et  al. analyzed 
the primary radiation injury response of the lung at 6 h, 1, and 
7 days after 18 Gy whole thorax irradiation in different mouse 
strains and characterized infiltrating T cell populations and their 
cytokine profile in the lung tissue and in the bronchoalveolar 
lavage fluid (BALF). The authors reveal lower T cell levels in 
TABLe 1 | Lymphocytes in the irradiated lung.
Background Cell type in the lung [days 
(d) post-irradiation]
Disease stage Reference
Murine model TH1 (CD4+ IFN-γ+) ↑ (d1, d7) Acute radiation response (140)
Thorax XRT TH2 (CD4+ IL-13+) ↑ (d1, d7)
18 Gy TH17 (CD4+ IL-17+) ↓ (d1, d7)




Murine model TH17 associated ↑ Pneumonitis (46)
Thorax XRT (IL-17, IL-23, IL-27) (d21)
15 Gy Treg ↑ (d21)
Murine model Treg ↑ (d21) Pneumonitis (142)
Thorax XRT CD4+ ↑ (d42, d84)
15 Gy
Murine model Treg ↑ (d30, d90, d180) Pneumonitis (185)
Thorax XRT Fibrosis
20 Gy
Murine model CD3+ ↑ (BALF) (d56, d112, d168) Pneumonitis (38)
Thorax XRT Fibrosis
15 Gy
Murine model Treg ↑ (d14, d30, d90, d180) Pneumonitis (81)
Thorax XRT Fibrosis
20 Gy
Murine model Treg ↑ (d210) Fibrosis (35)
Thorax XRT
15 Gy
Patient study CD4+ ↑ (BALF) (d30–d90) Pneumonitis (40)
2 Gy/day, 5 days/week, total 45–50 Gy
Patient study CD4+ ↑ (BALF) (d14) Pneumonitis (42)
2 Gy/day, 5 days/week, total 50–60 Gy CD8+ ↑ (BALF) (d14)
Patient study CD4+ ↑ (BALF) (d15) Pneumonitis (39)
1.8–2 Gy/day, 5 days/week, total 45–50 Gy CD8+ ↑ (BALF) (d15)
Murine (C57BL/6), rat, and patient studies revealing the presence of T lymphocytes during radiation-induced early and late adverse effects in the lung.
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the BALF and increased numbers of infiltrating TH1 and TH2 
cells in the lung at day 1 and 7 (140). Another murine study 
from Zheng et  al. uncovered a more delayed reconstitution of 
CD4+ T cells compared to that of CD8+ T cells upon low dose 
total body irradiation (2.5 Gy); furthermore, TH1 reconstitution 
was also impaired, whereas TH17 and Treg cells were elevated 
(141). In an own study, we showed that a 15  Gy whole thorax 
irradiation in mice led to a slight decrease in the percentage 
of CD3+ T cells in the lung at day 10 and 21 post-irradiation. 
In line with these findings, we found significant decreased levels 
of CD3+ T cells, including CD4+ and CD8+ T cells, at these time 
points in peripheral lymphoid organs like cervical lymph nodes 
and the spleen (142).
Altogether, these studies highlight that lymphocyte subsets 
differ in their rates of radiosensitivity, recovery, and infiltration 
during different disease stages suggesting that they may have a 
distinct contribution to the dynamic changes in the environment 
in the irradiated lung tissue.
Lymphocyte Responses to Signals from 
the irradiated Lung
Damage-Associated Molecular Patterns (DAMPs)
In the past decade, several studies revealed how the immune 
system recognizes sterile tissue damage. Bianchi demonstrated 
how sterile tissue stress and damage in general led to the release 
of DAMPs (143). These endogenous “danger signals” induce and 
dictate an immune response to orchestrate repair, growth, and 
tissue homeostasis after damage (144, 145).
Besides this direct effect of IR, the response of the damaged 
resident tissue cells toward irradiation, e.g., epithelial cells, 
endothelial cells, or smooth muscle cells, involves a systemic 
“danger signal” that orchestrates immune cell recruitment and 
tissue repair (34). The radiation-induced oxidative injury in the 
lung and the release of DAMPs induce resident cells to secrete 
inflammatory and chemotactic cytokines. Human and murine 
studies revealed that DAMPs in the injured lung include among 
others extracellular heat shock proteins, S100 proteins, defensins, 
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high-mobility group box-1 (146), extracellular nucleotides and 
nucleosides (35), as well as extracellular matrix (ECM) com-
ponents like fibronectin, hyaluronan, uric acid, and surfactant 
proteins (37, 147). This is in line with findings from other studies 
dealing with lung injury, induced, for example, by smoke (148) or 
mechanical ventilation (149). Furthermore, animal studies with 
BLM-induced alveolitis revealed elevated levels of hyaluronan 
in the BALF and lung tissue on day 5 and was paralleled by an 
increased influx of polymorphonuclear leukocytes in the BALF 
and an interstitial–alveolar edema (150, 151).
For radiation-induced lung injury it has been described 
that the released DAMPs act through signaling via P2X, P2Y 
receptors, toll-like receptors (TLR-2 and TLR-4), receptor for 
advanced glycation end-products, and NOD-like receptors 
(NLRP3), respectively (152). Consistent with a role of TLR 
signaling in radiation-induced lung disease, Myd88 knockout 
mice displayed increased as well decreased fibrosis development 
depending on the type of injury induced. In a BLM-induced lung 
injury model, Myd88 knockout mice showed attenuated fibrosis 
and reduced cell infiltration in contrast to WT mice (136). 
In contrast, a study from Brickey et al. revealed that Myd88 was 
protective in irradiated lungs and that irradiated Myd88−/− mice 
had increased pro-fibrogenic factors and TH2 cytokines and dis-
played enhanced fibrosis levels at 24–27 weeks post-irradiation 
compared to WT mice (137).
Thus, the release of DAMPs, activators of an inflammatory 
cascade, leads to recruitment of inflammatory cells, leading 
to tissue inflammation, the so-called radiation-induced acute 
phase.
Cytokines/Chemokines with Impact on  
Lymphocyte Recruitment or Function
Moreover, thoracic irradiation triggers a rapid upregulation of 
the transcriptional regulator NFκB resulting in the production 
of pro-inflammatory cytokines (e.g., IL-6, IL-1α, IL-1β, TNF-α, 
and IFN-γ) within minutes to hours post-irradiation, at least at 
the mRNA level (34, 133, 153–155). However, as highlighted 
above, mouse strains differ in their cytokine profile after lung 
irradiation. Radiation induced distinct temporal changes in 
diverse cytokines in the pulmonary fibrosis-sensitive C57BL/6 
mice compared to C3H mice (133). Rübe and colleagues 
demonstrated in a murine study that cells from the bronchiolar 
epithelium are a source for IL-6, TNF-α, and IL-1α in irradiated 
lungs (31). In line with these observations, Ao et al. described 
elevated IL-6 levels in the lungs of C57BL/6 model at 6 h post 
thorax irradiation with 12 Gy. In contrast, Paun et al. did not 
detect an increase in IL-6, IL-1β, IL-13, IL-17, and IFN-γ after 
6 h post thorax irradiation with 18 Gy. These conflicting data 
highlight that the early stress response of the irradiated lung 
tissue requires further definition.
It is assumed that secreted mediators recruit immune cells, 
including neutrophils, granulocytes, macrophages, and lympho-
cytes, into the damaged tissue. In this context, a recent murine 
study described that the radiation-induced early lung inflamma-
tion was accelerated by induction of the inflammasome (Nlrp3, 
caspase 1, IL-1α, and IL-1β), highlighting the contribution of 
an early innate response (156). Exposure of lung tissue to IR 
triggered an increased influx of lymphocytes (30, 39, 140, 157). 
One of the driving forces of lymphocyte infiltration into the 
lung is the chemokine (C-C motif) ligand 18 (CCL18). Patients 
suffering from different lung diseases displayed elevated levels 
of CCL18, and these were associated with T cell recruitment 
(158–160). CCL18 is also known as pulmonary and activation-
regulated chemokine; overexpression of CCL18 by intratracheal 
instillation of adenoviral vector AdV–CCL18 and subsequent 
overexpression of CCL18 in a murine BLM-induced injury 
model uncovered that CCL18 is highly selective for T cells and 
attracts these cells into the injured lung (161). Other potent 
chemoattractants that have been described to induce lymphocyte 
recruitment to a damaged lung tissue include the monocyte che-
moattractant protein 1, IL-16, thymus and activation-regulated 
chemokine, macrophage-derived chemokine, CCL1 (I-309), 
CCL5 (RANTES), and stromal cell-derived factor 1 (46, 154, 
162–164). In the injured tissue, the infiltrating lymphocytes get 
activated, start secreting diverse mediators, and finally contribute 
to a complex inflammatory milieu characteristic for pneumonitis.
As described above, various factors in the changing microen-
vironment of the irradiated lung have an impact on the response 
of recruited T lymphocytes that can act either in a pro- or in an 
anti-inflammatory way. For example, Paun et  al. investigated 
pulmonary T helper cell populations during the acute radiation 
response of the lung after 18  Gy whole thorax irradiation in 
C57BL/6 mice and uncovered that TH1 (CD4+ IFN-γ+) and TH2 
(CD4+ IL-13+) cells were increased at 1 and 7  days, but not at 
6 h post-irradiation. Furthermore, they found a decrease in TH17 
(CD4+ IL-17+) cells at 6 h, 1, and 7 day post-irradiation (140). 
Own investigations revealed the appearance of IL-17-expressing 
CD4+ T cells and CD4+FoxP3+ T-lymphocytes in the lung tissue 
of C57BL/6 mice at 21 days after whole thorax irradiation with a 
single high dose of 15 Gy (46).
During the early pneumonitic phase between 3 and 12 weeks 
post-irradiation (127) recruited T lymphocytes secrete TH1-like, 
pro-inflammatory TNF-α, IFN-γ, IL-2, and lymphotactin to 
attract and activate more immune cells to the site of damage 
(165). IFN-γ, for example, activates “classically activated” mac-
rophages (M1) with high nitric-oxide synthase 2 expression but, 
on the other hand, shows suppressive effects on myofibroblasts 
and inhibits the production of ECM proteins (166, 167). Besides 
this classical TH1 response, a pro-inflammatory TH17-dominant 
response was observed after thoracic irradiation in mice. Cytokine 
levels of IL-16, IL-17, IL-23, and IL-27 were elevated 3  weeks 
post-irradiation where they might promote chronic inflamma-
tion and tissue damage (46).
The observed findings reveal that besides the early induction 
of cytokines like IL-1, IL-6, and TNF-α primarily lymphoid TH1 
and TH17 responses contribute to the pro-inflammatory, pneu-
monitic phase.
Reconstitution of Lymphocytes  
in the irradiated Lung
Of course, the imbalance in the hematopoietic compartment after 
exposure to IR needs to be restored. Interestingly, the overall 
recovery rate of different lymphocyte subsets varies in different 
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organs and is chemokine dependent (168). For example, Santin 
et al. analyzed blood samples from irradiated patients with squa-
mous cervical cancer: in this study CD8+ cells recovered in the 
blood faster than CD4+ cells over a time period of 40 days after a 
5-week radiation treatment (169). This is consistent with earlier 
studies suggesting a prolonged reduction in lymphocyte prolif-
eration, a persistent reduction in cell counts, or even an inversion 
of the CD4+/CD8+ ratio after whole body irradiation and thorax 
irradiation in breast cancer patients (170–173). Furthermore, in 
a recent study with 1,423 lung cancer patients, Yan et al. found 
significantly increased levels in blood CD3+ T-cells, especially 
CD8+ T cells, compared to CD4+ T cells in the patients 3 months 
after RT of the lung (174). Analysis of total lymphocytes in 
limited-stage small cell lung cancer (LS-SCLC) patients revealed 
a decrease in total lymphocytes during RT followed by recovery 
after the end of treatment; interestingly, the authors correlated the 
severity of radiation-related lymphopenia to treatment outcome 
revealing a potential use of radiation-related lymphopenia for 
prediction of poor survival in LS-SCLC (175).
Chronic effects of Thoracic irradiation 
on Lymphocytes in the Lung
TH Subsets
Substantial changes in the lung environment are observed dur-
ing the chronic inflammatory and fibrotic phase in the irradi-
ated lung. It is thought that in this context the shift from a TH1 
cytokine profile toward a TH2 cytokine profile could be a key 
event. The signature of TH2 cytokines IL-4, IL-5, IL-10, and IL-13 
is known to convey strong anti-inflammatory and pro-fibrotic 
effects, to mediate fibroblast activation, and activate “alternatively 
activated” macrophages (M2) with high arginase-1 expression 
(43, 166, 176, 177). Of further interest is a recent study from 2016 
showing that radiation-induced lung fibrosis in a tumor-bearing 
mouse model was associated with enhanced type 2 immunity 
(178). In this study, the authors revealed that GATA3 expression 
in tumors appeared to affect the response to the normal lung tis-
sue to radiation-induced damage. Lung fibrosis was more severe 
in tumor-bearing mice than in normal mice post-irradiation, 
highlighting that the enhanced type 2 immunity in tumors 
appeared to influence the outcome of radiation damage.
Despite the known pro-fibrotic actions of the IL-4/IL-13 
axis, a recent study suggested a potential protective role for the 
IL-13Rα1 in a murine model of BLM-induced fibrosis; here, 
the authors speculated that IL-4 and/or IL-13 may act through 
the type 2 IL-4 receptor to regulate epithelial cell healing and 
immune responses to lung damage and further protection against 
pulmonary fibrosis (179). In line with this study, Han et al. also 
identified increased expression of the type 2 key transcription 
factor GATA3 in C57BL/6 mice that had received 12 Gy thorax 
irradiation (176).
Interestingly, first data about the role of the subset of TH9 
cells have been obtained in a model of pneumonitis and fibrosis 
induced by silica particles; these suggest that IL-9 expression may 
reduce lung fibrosis and type 2 immune polarization (180). Taken 
together, until now the impact of the cytokine production of TH1, 
TH2, TH9, and TH17 subsets in radiation-induced pneumopathy 
has not been fully described and understood, but it is highly likely 
that TH2-driven responses are a key event of radiation-induced 
fibrosis development.
Up to now, there is only limited information available about 
the impact of the B cell compartment on the outcome of radiation-
induced pneumopathy and other models of fibrotic lung disease. 
A recent transcriptome analysis of irradiated mouse lungs at 
24 weeks after exposure to IR revealed that genes associated with 
B cell proliferation and activation were significantly induced in 
irradiated lungs of fibrosis-prone C57BL/6 mice suggesting a 
possible role of B cells in radiation-induced pneumopathy (181). 
Interestingly, deficiency in the B cell surface molecule CD19 in 
mice reduced the susceptibility to BLM-induced fibrosis, whereas 
CD19 overexpression in mice aggravated BLM-induced fibrosis 
(182). In contrast, B cells under the influence of IL-9 participated 
in the protection against lung fibrosis in a murine model of silica 
particle-induced lung fibrosis, and their protective effect was 
associated with the overexpression of prostaglandin-E2 (PGE2) 
in macrophages (183). Interestingly, PGE2 itself is thought to be 
anti-fibrotic due to its suppressing effects on fibroblast prolifera-
tion and its ability to reduce the expression of collagen mRNA 
(184). These controversial findings highlight the need for further 
studies to clarify the protective or destructive role of B cells in 
radiation-induced pneumopathy and the involved mediators.
TGF-β and Treg
Besides the influx of T helper lymphocytes, the Treg subset also 
infiltrates the irradiated lung tissue, where it is thought to suppress 
an exaggerated inflammation (80, 81, 142, 185). Treg can be gener-
ally induced by TGF-β (186). This cytokine is released early after 
tissue injury by type II pneumocytes, fibroblasts, and immune 
cells (187, 188), but the latent form can also be activated by 
radiation in vitro (189). During this early phase TGF-β is thought 
to function mainly as a pro-inflammatory mediator to attract 
neutrophils but may also provide signals for limitation of tissue 
inflammation, e.g., by inducing Treg (190, 191). During the later 
remodeling phase (24–30 weeks), macrophages can be a source 
for TGF-β; during this phase TGF-β is known to promote repair 
processes and to favor fibrosis. This might explain the observed 
biphasic appearance of Treg in the acute and in the chronic phase 
of radiation-induced lung injury described recently (35, 142, 
185). Vice versa, Treg can also produce TGF-β as well as IL-10, 
revealing their suppressive capacity and suggesting an additional 
pro-fibrotic action (79, 192). In this context, it is discussed that 
besides TGF-β epithelial cell-derived IL-18 and IL-33—released 
after tissue damage—might be also important for the induction 
and maintenance of Treg. The activation of Treg via IL-33 and its 
receptor suppression of tumorigenicity 2 (ST2, also known as 
IL33R, IL-1RL1) lead to a TH2-like character, expressing GATA3 
and secreting TH2 cytokines IL-5 and IL-13. Furthermore, IL-18- 
and IL-33-activated Treg showed higher suppressive capacity by 
enhanced activation and secretion of the anti-inflammatory and 
pro-fibrotic cytokines IL-10 and TGF-β as well as amphiregulin 
(AREG) (193–195). Thus, we speculate that IL-18/IL-33-driven 
Treg-activation contributes to tissue repair and a pro-fibrotic 
actions in the lung. Further studies are needed to confirm this in 
a radiation-induced lung injury model.
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It has been shown that Treg contribute to fibrotic diseases in the 
lung such as radiation-induced, BLM-induced lung injury and 
IPF by modulating the microenvironment through mechanisms 
involving among others induction of Th17 responses, shifting the 
IFN-gamma, IL-12/IL-4, IL-5 balance, and promoting endothe-
lial to mesenchymal transition (79–81, 196, 197).
Nevertheless, the role of Treg in pneumopathy remains to be 
further elucidated as these cells play distinct roles in different 
disease stages and disease models (79, 80, 192, 196, 198, 199). 
While depletion of CD4+CD25+ T cells with an anti-CD25 
antibody during an early stage of BLM-induced lung disease 
reduced the levels of inflammatory cells, collagen deposition, 
TGF-β, and lung fibrosis in mice, Treg depletion during later 
stages in this model led to a more pronounced infiltration of 
inflammatory cells and increased fibrosis scores (196). This 
highlights a disease-promoting effect of CD4+CD25+ T cells 
during the acute phase of BLM-induced lung disease and 
a protective role of these cells during the fibrotic phase. By 
contrast, abrogation of the long-lasting (6 months) increase in 
CD4+CD25+ Treg observed in irradiated lungs of C57BL/6 mice 
by long-term CD4+CD25+ T cell depletion with an anti-CD25 
antibody reduced the increase in fibrocytes and attenuated 
radiation-induced lung fibrosis (80). In this model, deple-
tion of CD4+CD25+ T cells covered both, the pneumonitic 
and the fibrotic phase so that the two publications are not 
directly comparable. Nevertheless, the latter report implicates 
that a disease-promoting effect of CD4+CD25+ T cells is pre-
dominant in radiation-induced lung disease. To our present 
view, the suppressive properties of Treg are needed during the 
pneumonitic phase to dampen an overwhelming and excessive 
pro-inflammatory response that is however initially needed to 
induce repair and regeneration. Yet, during the chronic disease 
stage under the influence of a changing environment, Treg 
seem to adopt a pathologic character, secreting mediators like 
IL-10, TGF-β, and AREG, thereby contributing to a fibrosis-
promoting intercellular cross talk. Our current hypothesis of 
the underling mechanisms is summarized in Figure 2; depend-
ing on the cell type the persistent damage caused by irradiation 
of resident cells will result either in a delayed partial cell loss 
(e.g., endothelial cells, alveolar epithelial cells) or in a chronic 
cell activation (e.g., MSC, fibroblasts) thereby driving chronic 
environmental changes (e.g., chronic increase in tissue hypoxia, 
adenosine, hyaluronan, macrophage-derived IL-10 and TGF-β, 
and epithelial-derived IL-18/IL-33) that promote among others 
the generation and a phenotypic adaptation of Treg. Under such 
conditions, the phenotype of ILC—like that of Treg cells and 
myeloid cells—may shift toward a disease-promoting phenotype 
supporting chronic lung inflammation and pulmonary fibrosis 
in irradiated lung tissue. It is therefore highly likely that the 
distinct roles of lymphocytes and Treg in BLM-induced versus 
radiation-induced pulmonary fibrosis may be due to differences 
in impact of an acute but reversible damage by the drug BLM 
and a chronic, persistent impact of IR on the environmental 
changes and associated immune changes.
The findings reported so far highlight the need for more 
detailed mechanistic analyses about the role of Treg for adverse 
late effects of IR in the lung.
THeRAPeUTiC APPROACHeS FOR 
RADiATiON-iNDUCeD PNeUMOPATHY
There is increasing evidence that lymphocytes play a role in 
RT-induced adverse late effects in the lung. Thus, these cells 
or the mediators associated with their pro- or anti-fibrotic 
function may constitute valuable targets for the prevention or 
treatment of radiation-induced lung disease. However, so far 
there is only little knowledge about the use of specific lympho-
cyte subpopulations or their mediators as potential diagnostic 
or predictive biomarkers for early or late adverse effects of IR 
in the lung. Consequently, so far treatment strategies targeting 
immune cells or associated mediators suspected to participate 
in disease pathogenesis are only tested in preclinical investiga-
tions in mice.
Instead, current treatment options for patients suffering from 
radiation-induced pneumonitis are limited to the symptomatic 
administration of anti-inflammatory drugs such as glucocorti-
coids thought to limit the toxic effects of the overwhelming inflam-
mation by reducing the levels of pro-inflammatory cytokines, 
chemokines, and growth factors. But, these anti-inflammatory 
therapies may also indirectly impact on lymphocyte responses, 
their activation state, or both.
Current Treatment with an impact 
on Lymphocyte Responses
Experimental studies in patients mostly aim or address either 
the impact of the treatment on radiation-induced pneumonitis 
or on radiation-induced lung fibrosis, respectively. However, 
immunomodulatory strategies will mostly influence both, 
early and late disease stages. For example, treatment of patients 
developing pneumonitis with anti-inflammatory drugs such as 
glucocorticoids and pentoxifylline (PTX) will also impact on the 
chronic radiation-induced immune changes thereby potentially 
influencing progression to lung fibrosis.
Due to their anti-inflammatory and immunosuppressive prop-
erties, glucocorticoids such as dexamethasone and prednisone are 
widely used after lung irradiation in symptomatic patients. Both 
drugs affect the expression of inflammation-associated genes by 
interaction with the steroid receptor. For example, glucocorticoid 
treatment involves the inhibition of the NF-κB pathway (200) as 
well as inhibition of the expression of IL-17A, TGF-β, IL-6, and 
TNF-α, thereby reducing radiation-related inflammation (201). 
Furthermore, dexamethasone also reduced the deposition of col-
lagen in the lung tissue of irradiated mice (201, 202).
Pentoxifylline and alpha-tocopherol (vitamin E; Vit E) also 
exert anti-inflammatory actions and have already been used 
in patients. PTX is a xanthine derivative that acts by inhibit-
ing TNF-α, IL-1, fibroblast growth factor, TGF-β as well as the 
SMAD pathway, whereas Vit E is known to counteract TGF-β 
and the SMAD signaling (203). In a study with 40 patients PTX 
was shown to provide significant protection against the early and 
late adverse late effects of RT in the lung (204). Furthermore, 
in another randomized trial study radiation-induced adverse 
effects were more frequent for all disease stages in the untreated 
control group of patients receiving irradiation alone compared 
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to the groups where irradiation was combined with PTX and Vit 
E (205).
Another interesting approach that is already being explored 
since 1990 is the use of angiotensin-converting enzyme (ACE) 
inhibitors to treat radiation-induced adverse late effects in the 
lung (206). Interestingly, these inhibitors also interfere with 
immune responses, e.g., in T lymphocytes (207, 208). The 
membrane-bound ACE hydrolyzes a spectrum of substrates 
with physiologic relevance like angiotensin, bradykinin, or 
neurotensin (209) and is expressed in human CD4+ and CD8+ 
T-lymphocytes but not in B cells (210). Investigations with 
ACE inhibitors like captopril and ramipril in patients revealed a 
potential benefit in decreasing the incidence of radiation-induced 
pneumonitis (211–214). Unfortunately, a recent clinical study 
from 2016 validating the protective effect of the ACE inhibitor 
captopril in radiation-induced lung toxicity failed due to low 
accrual and a high number of patients who had to be excluded 
from the analysis. Nevertheless, the study confirmed safety of 
the ACE inhibitor treatment; the authors suggest that the use of 
newer ACE inhibitors (e.g., enalapril or lisinopril) during RT may 
be suited to solve the problems identified in their trial (215).
Other immunosuppressive agents that have been tested ear-
lier preferentially in single case reports are cyclosporin and aza-
thioprine. Cyclosporin is a common immunosuppressive agent 
that acts on CD4+ T lymphocytes by inhibiting the transcription 
of the interleukin-2 gene (216). Cyclosporin has already been 
described in 1991 as a treatment option in interstitial lung dis-
ease (217). Moreover, treatment with cyclosporine successfully 
reduced the symptoms of radiation-induced pneumonitis in a 
case study (218). Instead, case studies testing the use of azathio-
prine, a drug with suspected inhibitory effects on T lymphocyte 
formation and B lymphocyte proliferation (219, 220), revealed 
either a beneficial effect (221) or no effect in radiation-induced 
pneumonitis (222).
So far, current treatment options are limited and focus on the 
control of overwhelming pro-inflammatory responses during 
the pneumonitic phase. Furthermore, risk factors are not well 
understood, and predictive biomarkers are lacking. This high-
lights the urgent need for further preclinical and clinical studies 
to gain a more comprehensive understanding of the underlying 
mechanisms as well as the complex cellular cross talk and the 
mediators driving disease pathogenesis, if we aim to define pre-
dictive biomarkers and novel therapeutic approaches.
Current Research and Future Perspectives
Anti-inflammatory drugs are effectively reducing the symptoms 
of radiation-induced pneumonitis, and most patients completely 
recover from pneumonitis. However, many patients suffering 
from thorax-associated neoplasms, particularly lung cancer, or 
patients with chronic respiratory disease have an increased risk to 
develop lethal pneumonitis. Therefore, it is important to uncover 
diagnostic and prognostic biomarkers for radiation-induced 
lung disease, particularly lethal pneumonitis. Several patient-
associated factors have been described to be associated with an 
increased risk to develop (severe) radiation pneumonitis such as 
the patient age and fitness, additional disease (e.g., tumor, COPD), 
as well as treatment (e.g., XRT fractions, drug administration) 
(223–225). Furthermore, several potential biomarkers such 
as pulmonary function, dose–volume histogram, end/pre-RT 
plasma levels of TGF-β1, IL1α, and IL6 have been described that 
may be suited to predict a higher risk for radiation-induced lung 
toxicity (226, 227). A promising novel approach to predict and 
understand genetic risk factors for radiation-induced toxicity 
may be the use of radiogenomics (228).
Despite the high efficacy of anti-inflammatory drugs in reduc-
ing the symptoms of radiation-induced pneumonitis, patients 
recovering from pneumonitis still have the risk of developing 
subsequent pulmonary complications. However, effective mech-
anism-based options for the treatment of pulmonary fibrosis are 
still limited (229). Therefore, another important topic of current 
research is to develop effective therapeutic strategies to prevent 
or treat radiation-induced lung fibrosis (223, 230); experimental 
approaches mostly target radiation-induced formation of free 
radicals, cell death, or specific cytokines or growth factors, 
respectively.
Importantly, a review from 2010 highlighting patient data as 
well as experimental studies mentioned already that “One last 
target that may need further investigation is that of the immune 
system, more specifically the alteration in immune responses…” 
(231). As shown in Table  1, the majority of studies in public 
databases identified CD4+ T cells and Treg as key populations 
among lymphocytes infiltrating lungs during radiation-induced 
pneumonitis and fibrosis. Though molecular approaches to 
reduce radiation-induced lung fibrosis by inhibiting pro-fibrotic 
mediators (e.g., TGF-β) are known to modulate lymphocyte 
induction/activation (232), 6  years later, our knowledge about 
the role of diverse lymphocytes during fibrosis is still limited. 
Targeted approaches to modulate lymphocyte recruitment, 
activation, or signaling are rare and still limited to preclinical 
studies in various murine models of chronic respiratory disease 
or fibrosis-associated disease, respectively.
One promising approach is to target the cytokine IL-17A 
as it has been suggested that the protective effects of anti-
inflammatory drugs such as dexamethasone involve the reduc-
tion of IL-17A (233). In this context, treatment with an antibody 
against IL-17A reduced IL-17A, TGF-β, and IL-6 concentrations 
and alleviated radiation-induced pneumonitis and subsequent 
fibrosis in mice (233). Another interesting approach to target 
IL-17 might be the use of phosphodiesterase-4 inhibitors such 
as roflumilast that prevent the breakdown of cAMP thereby 
inhibiting fibroblast activation and TGF-β induction (234). In a 
murine model of chronic asthma, treatment with roflumilast 
reduced the expression of IL-17A, TNF-α, GM-CSF, and IL-6 
to a similar extent as dexamethasone implying a potential use of 
roflumilast for the treatment of adverse events in the irradiated 
lung (235).
Another potential target currently in the focus of research 
of other diseases including cancer are Treg. As mentioned above, 
Treg can be induced by TGF-β and also secrete or bind TGF-β 
(236, 237). This suggests that targeting Treg might be suited to 
counteract radiation-induced adverse late effects in the lung and 
other diseases rich in tissue TGF-β-levels such as, skin, liver, and 
kidney (238–240). In support of this assumption, abrogation of 
the long-lasting (6 months) increase in Treg by depletion with an 
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anti-CD25 antibody counteracted the development of radiation-
induced fibrosis in mice (80) thereby corroborating findings 
in other fibrotic diseases (79). Still, further studies are needed 
to strengthen these results with respect to radiation-induced 
(pulmonary) fibrosis. The above findings of Xiong et  al. are of 
particular interest because several studies highlight the potential 
importance of Treg depletion in enhancing antitumor immunity 
during RT (241, 242). One major challenge in targeting Treg will 
be defining the optimal treatment schedule, since Treg might also 
be beneficial in counteracting exaggerated inflammation during 
the pneumonitic phase (142).
In this context, we recently showed that the CD73/adenosine 
axis is a potential target in radiation-induced lung fibrosis. 
Lymphocytes, especially Treg, showed high CD73 expression 
after irradiation, and a CD73 deficiency in mice led to reduced 
expression of pro-fibrotic mediators like TGF-β and osteopontin 
during the fibrotic phase (35). Further unpublished data reveal 
that genetic deficiency of CD73 also precludes the accumulation 
of alternatively activated macrophages in prefibrotic macrophage 
clusters in the irradiated lung tissue (deLeve and Wirsdörfer, 
unpublished observations). The contribution of the CD73/
adenosine pathway in fibrosis has already been described for 
BLM-induced pneumopathy and in other fibrotic diseases 
(243–245). Adenosine can bind to four different adenosine 
receptors to induce anti-inflammatory and pro-fibrotic actions. 
It is known that it inhibits lymphocyte proliferation, activation, 
and cytokine secretion. Furthermore, it promotes the induction 
and activation of Treg, highlighting its role in immunomodula-
tion (246). In our hands, therapeutic targeting of the CD73/
adenosine pathway by either enzymatic inhibition of adenosine 
accumulation or antibody blockade of adenosine-converting 
CD73 attenuated fibrosis development upon a single high-dose 
(15  Gy) whole thorax irradiation of C57BL/6 mice (35). The 
complex mechanism of the adenosine action in the pathogenesis 
of fibrotic diseases is not fully understood and is under current 
investigation. Importantly, the CD73/adenosine pathway has 
recently emerged as a novel immune checkpoint that tumor cells 
use to dampen intratumoral immune responses (247). Therefore, 
pharmacologic strategies for modulating CD73 or adenosine may 
limit radiation-induced adverse late effects presumably without 
increasing or even decreasing radiation resistance of tumor cells 
(35).
A novel potential candidate for future treatment options might 
be the group of ILC. ILC seem to play a critical role in lung inflam-
mation, tissue remodeling, and fibrosis development thereby 
revealing a therapeutic potential of modulating ILC responses in 
the lung. Although it is highly likely that ILC may also impact 
radiation-induced lung disease, their role has not yet been inves-
tigated. Further studies are needed to clarify their contribution to 
acute and chronic disease stages after irradiation and to uncover 
a therapeutic potential in the context of ILC signaling, e.g., by 
targeting IL-33 or ST2. The cytokine IL-33 is important in innate 
and adaptive immunity and contributes to tissue homeostasis 
and is induced under environmental stress. IL-33 can be released 
by epithelial cells after tissue damage and is a trigger of tissue repair 
induced by ILC2 and Treg (193). Regarding lung fibrosis, it was 
revealed that IL-33 enhanced BLM-induced fibrosis by increasing 
the levels of the TH2 cytokines IL-4, IL-5, or IL-13 (103), leading 
to the assumption that ILC2 or TH2 cells are induced. Moreover, it 
was shown that treatment with an anti-IL-33 antibody attenuated 
BLM-induced lung inflammation and fibrosis (104). A current 
review nicely summarizes the role of IL-33 and ST2 in health and 
disease highlighting its potential for therapeutic intervention also 
in fibrotic lung disease (193). The observations on IL-33 activity in 
the lung with an impact on TH2 responses and tissue repair make 
it highly likely that IL-33/ST2 signaling may also impact on radi-
ation-induced lung fibrosis. Further studies are needed to clarify 
the role of this signaling axis in radiation-induced pneumopathy.
Another interesting and novel therapeutic option to treat 
radiation-induced adverse effects in the lung with a potential 
interaction with lymphocytes is the therapeutic application 
of MSC or of microvesicles/exosomes secreted by MSC (36, 
248–252). This approach is based on the initial observation that 
healthy resident MSC are important to lung homeostasis and 
protect the lungs after injury among others by immunomodula-
tion mostly through paracrine mechanisms (253–256). However, 
when resident-specific endogenous MSC are damaged or lost, 
e.g., by differentiation into myofibroblasts, this cell population 
contributes to TGF-β production, tissue remodeling, and fibrosis 
in various models, including thoracic irradiation, exposure to 
BLM, and IPF (37, 257–262). In this context, impaired regulation 
of effector T cell proliferation upon loss of resident pulmonary 
MSC has been implicated in the development of BLM-induced 
fibrosis (257).
Instead exogenously applied MSC may exert tissue protec-
tive effects by differentiating into an epithelium-like phenotype 
and replacing damaged cells, although our own data hint to a 
minor contribution of this effect to their protective effects (36, 
263). Interestingly, recent findings highlight the ability of MSC 
to transfer (healthy) organelles or molecules by direct cell-to-
cell contact through tunneling nanotubes or by the release of 
exosomes or microvesicles, respectively (255).
Several reports including own studies revealed that MSC 
show anti-fibrotic and protective effects in the irradiated lung, 
and current reviews highlight a potential therapeutic benefit of 
MSC therapy for the treatment of radiation-induced and BLM-
induced tissue damage (36, 37, 248, 263). In our hands, adoptively 
transferred MSC normalized certain aspects of radiation-induced 
immune deviation in the lung tissue, normalized vascular func-
tion, and attenuated radiation-induced pulmonary fibrosis (36, 
37). We and others showed that the anti-inflammatory and anti-
fibrotic action of MSC is mediated by the inhibition of TNF-a, 
IL-1alpha, and interleukin 1 receptor antagonist (249, 251), 
stimulating the secretion of hepatocyte growth factor (HGF) and 
PGE2 (250, 252) and restoration of the superoxide dismutase 1 
expression (37).
Generally, MSC might also exert protective effects during 
pneumonitis and fibrosis development due to their antiprolif-
erative effects (253) and their suppressive capacity on innate and 
adaptive immune responses (254). The suppressive capacity on 
lymphocytes is mediated by the secretion of soluble factors like 
HGF, PGE2, truncated CCL-2, IL-10, and PD-1 ligation thereby 
inhibiting CD4+ T cell proliferation and the polarization toward 
a TH1 and TH17 phenotype (254). Due to a potential inhibition of 
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TH1 and TH17 cells during radiation-induced pneumonitis, MSC 
might dampen an excessive immune response. This effect may 
be complemented by the ability of MSC to favor the develop-
ment of a TH2 phenotype and Treg (254, 264). This effect could be 
beneficial during the pneumonitic phase but may be disadvanta-
geous during the fibrotic phase. We speculate that by dampening 
tissue inflammation and remodeling and restoration of resident 
cell function, MSC limit resident cell loss/dysfunction, chronic 
inflammation, and fibrosis-promoting environmental changes. 
In this context, others and we described that MSC treatment has 
protective effects in the lung due to a transdifferentiation into 
an epithelium-like phenotype (263) and by the protection from 
endothelial cell loss (37), respectively.
Finally, another experimental approach to reduce DNA 
damage-induced late effects in the lung with an impact on lym-
phocytes is the use of the lysophosphatidic acid receptor (LPA1) 
antagonist AM966: treatment with AM966 revealed reduced lung 
injury, vascular leakage, lymphocyte recruitment, and fibrosis 
development at 14 days after BLM treatment (265). However, this 
drug has not yet been tested in radiation-induced lung disease.
Nevertheless, current studies investigating the role of lympho-
cytes and their inducers and mediators as therapeutic targets in 
radiation-induced adverse effects in the lung are still rare. This 
might be due to insufficient knowledge on the beneficial and 
adverse role of specific lymphocytes subsets in different stages of 
disease pathogenesis.
FiNAL ReMARKS
Up to now, mechanistic knowledge about the role of lympho-
cytes in radiation-induced pneumopathy is still limited, and no 
reliable diagnostic or predictive biomarkers for beneficial and 
adverse effects of specific lymphocyte subsets are available to 
date. Nevertheless, preclinical and clinical investigations indicate 
that radiation-induced immune changes are important to the 
outcome of RT and that lymphocytes contribute to the beneficial 
and adverse effects of IR in tumors and normal tissues, including 
the lung.
We hypothesize that radiation-induced acute damage to resi-
dent cells including progenitor cells of mesenchymal origin and a 
perpetual cascade of cytokines/chemokines triggers immune cell 
recruitment and activation to promote tissue repair. However, in 
cases where the immune response cannot be controlled by anti-
inflammatory cells such as Treg or M2-like macrophages, patients 
may develop pneumonitis. If this initial damage response is not 
sufficient to repair the radiation-induced damage, the persistent 
damage results in chronic inflammation and delayed changes 
of resident cells, such as epithelial-mesenchymal-transition, 
endothelial-mesenchymal-transition, activation of MSC, or 
even chronic (mitotic) cell death of endothelial cells and alveolar 
epithelial cells. The resulting delayed environmental changes 
involve among others tissue hypoxia (by chronic endothelial cell 
loss), chronic inflammation, and chronic increase in fibroblasts 
and fibrosis-promoting mediators such as adenosine, hyaluronic 
acid, and TGFβ. These changes act together in the generation/
activation of disease-promoting cell phenotypes such as activated 
myofibroblasts, pathologic Treg, or M2-like macrophages thereby 
promoting exaggerated ECM deposition and fibrosis develop-
ment (Figure 2).
Here, we want to stress that radiation-induced immune 
changes can be either pro-inflammatory (acute phase) or anti-
inflammatory/pro-fibrotic (chronic phase), and that lymphocytes 
exert distinct functions during radiation-induced pneumopathy 
(see Figure 1). We speculate that Treg might be beneficial during 
radiation-induced pneumonitis due to their suppressive action on 
pro-inflammatory cells as seen in hypersensitivity pneumonitis 
(266). In contrast, as outlined above current preclinical studies in 
diverse murine fibrosis models highlight a potential contribution 
of Treg in fibrosis development, and own work supports such a 
disease-promoting role also for radiation-induced pulmonary 
fibrosis (35). We therefore assume that these immunosuppressive 
cells or the environmental factors promoting their recruitment/
expansion may constitute promising therapeutic targets to pre-
vent or treat radiation-induced fibrosis. We are aware that the 
use of specific lymphocyte populations or associated signaling 
molecules as therapeutic targets is complicated by the fact these 
cells exert either beneficial or harmful roles. This depends on 
the disease stage, and potentially patient-specific genetic factors. 
Consequently this requires the careful definition of optimal treat-
ment schedules to avoid immune cell-associated complications 
during both, pneumonitis and fibrosis. We also want to point 
out that recently discovered lymphocyte subsets like ILC as well 
as signaling pathways like IL-33/ST2 are of interest due to their 
potential contribution to RT-induced pneumopathy highlighting 
the need of related studies.
Further important issues that also need to be addressed are 
(i)  the potential high intrinsic radioresistance of thorax-asso-
ciated solid tumors treated by thoracic RT and (ii) a potential 
tumor immune escape. Therefore, it is important to consider 
that any inflammation-modulating or immune cell-targeting 
strategy for the treatment of radiation-induced pneumopathy 
may alter the antitumor effect of RT or combined treatment 
strategies involving immunomodulation or immunoboost; 
unfortunately, this issue is mostly not addressed by preclinical 
studies investigating the mechanisms of radiation-induced 
normal tissue toxicity. Vice versa, a potential increased normal 
tissue toxicity of such antitumor treatments is not analyzed 
when studying new combination treatments in preclinical 
models. Therefore, there is a high need to develop appropriate 
preclinical models if we want to identify treatment strategies 
balancing radiation-induced tumor cell clearance and normal 
tissue protection. Nevertheless, we are convinced that a better 
understanding of radiation-induced immunomodulation in 
tumors and normal tissues will offer novel opportunities for 
widening the therapeutic window by targeting immune cells 
or immune-associated mediators that promote both, tumor 
growth/resistance and normal tissue  toxicity—of these, TGF-β 
and adenosine constitute perfect examples.
Taken together, it is important to deepen our knowledge about 
radiation-induced immune changes, including the modulation of 
lymphocyte recruitment, proliferation, and/or function of spe-
cific lymphocyte subsets during the different stages of radiation-
induced lung disease. Further studies are needed to optimize 
therapeutic strategies for the prevention or treatment of adverse 
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